250 related articles for article (PubMed ID: 20452213)
1. Agonist/antagonist modulation in a series of 2-aryl benzimidazole H4 receptor ligands.
Savall BM; Edwards JP; Venable JD; Buzard DJ; Thurmond R; Hack M; McGovern P
Bioorg Med Chem Lett; 2010 Jun; 20(11):3367-71. PubMed ID: 20452213
[TBL] [Abstract][Full Text] [Related]
2. Structural requirements for inverse agonism and neutral antagonism of indole-, benzimidazole-, and thienopyrrole-derived histamine H4 receptor ligands.
Schneider EH; Strasser A; Thurmond RL; Seifert R
J Pharmacol Exp Ther; 2010 Aug; 334(2):513-21. PubMed ID: 20484153
[TBL] [Abstract][Full Text] [Related]
3. Synthesis and structure-activity relationships of conformationally constrained histamine H(3) receptor agonists.
Kitbunnadaj R; Zuiderveld OP; De Esch IJ; Vollinga RC; Bakker R; Lutz M; Spek AL; Cavoy E; Deltent MF; Menge WM; Timmerman H; Leurs R
J Med Chem; 2003 Dec; 46(25):5445-57. PubMed ID: 14640553
[TBL] [Abstract][Full Text] [Related]
4. Histamine H4 receptor ligands and their potential therapeutic applications.
Kiss R; Keseru GM
Expert Opin Ther Pat; 2009 Feb; 19(2):119-35. PubMed ID: 19441913
[TBL] [Abstract][Full Text] [Related]
5. Major advances in the development of histamine H4 receptor ligands.
Smits RA; Leurs R; de Esch IJ
Drug Discov Today; 2009 Aug; 14(15-16):745-53. PubMed ID: 19477292
[TBL] [Abstract][Full Text] [Related]
6. Stereochemical diversity-oriented conformational restriction strategy. Development of potent histamine H3 and/or H4 receptor antagonists with an imidazolylcyclopropane structure.
Watanabe M; Kazuta Y; Hayashi H; Yamada S; Matsuda A; Shuto S
J Med Chem; 2006 Sep; 49(18):5587-96. PubMed ID: 16942032
[TBL] [Abstract][Full Text] [Related]
7. Cyclopropane-based stereochemical diversity-oriented conformational restriction strategy: histamine H3 and/or H4 receptor ligands with the 2,3-methanobutane backbone.
Watanabe M; Kobayashi T; Hirokawa T; Yoshida A; Ito Y; Yamada S; Orimoto N; Yamasaki Y; Arisawa M; Shuto S
Org Biomol Chem; 2012 Jan; 10(4):736-45. PubMed ID: 22120611
[TBL] [Abstract][Full Text] [Related]
8. Identification of 2-arylbenzimidazoles as potent human histamine H4 receptor ligands.
Lee-Dutra A; Arienti KL; Buzard DJ; Hack MD; Khatuya H; Desai PJ; Nguyen S; Thurmond RL; Karlsson L; Edwards JP; Breitenbucher JG
Bioorg Med Chem Lett; 2006 Dec; 16(23):6043-8. PubMed ID: 16990005
[TBL] [Abstract][Full Text] [Related]
9. Receptor-specific functional efficacies of alkyl imidazoles as dual histamine H3/H4 receptor ligands.
Kottke T; Sander K; Weizel L; Schneider EH; Seifert R; Stark H
Eur J Pharmacol; 2011 Mar; 654(3):200-8. PubMed ID: 21237145
[TBL] [Abstract][Full Text] [Related]
10. Selective histamine H₃ and H₄ receptor agonists exert opposite effects against the gastric lesions induced by HCl in the rat stomach.
Coruzzi G; Adami M; Pozzoli C; de Esch IJ; Smits R; Leurs R
Eur J Pharmacol; 2011 Nov; 669(1-3):121-7. PubMed ID: 21839070
[TBL] [Abstract][Full Text] [Related]
11. Interactions of histamine H1-receptor agonists and antagonists with the human histamine H4-receptor.
Deml KF; Beermann S; Neumann D; Strasser A; Seifert R
Mol Pharmacol; 2009 Nov; 76(5):1019-30. PubMed ID: 19720730
[TBL] [Abstract][Full Text] [Related]
12. Discovery of novel human histamine H4 receptor ligands by large-scale structure-based virtual screening.
Kiss R; Kiss B; Könczöl A; Szalai F; Jelinek I; László V; Noszál B; Falus A; Keseru GM
J Med Chem; 2008 Jun; 51(11):3145-53. PubMed ID: 18459760
[TBL] [Abstract][Full Text] [Related]
13. Piperazine modification in 2,4,6-triaminopyrimidine derivatives as histamine H4 receptor ligands.
Schreeb A; Walter M; Odadzic D; Schwed JS; Weizel L; Stark H
Pharmazie; 2013 Jul; 68(7):521-5. PubMed ID: 23923631
[TBL] [Abstract][Full Text] [Related]
14. Synthesis and functional characterization of imbutamine analogs as histamine H3 and H4 receptor ligands.
Geyer R; Kaske M; Baumeister P; Buschauer A
Arch Pharm (Weinheim); 2014 Feb; 347(2):77-88. PubMed ID: 24493592
[TBL] [Abstract][Full Text] [Related]
15. Functional Profiling of 2-Aminopyrimidine Histamine H4 Receptor Modulators.
Tichenor MS; Thurmond RL; Venable JD; Savall BM
J Med Chem; 2015 Sep; 58(18):7119-27. PubMed ID: 25993395
[TBL] [Abstract][Full Text] [Related]
16. Synthesis and structure-activity relationships of indole and benzimidazole piperazines as histamine H(4) receptor antagonists.
Terzioglu N; van Rijn RM; Bakker RA; De Esch IJ; Leurs R
Bioorg Med Chem Lett; 2004 Nov; 14(21):5251-6. PubMed ID: 15454206
[TBL] [Abstract][Full Text] [Related]
17. Molecular determinants of selective agonist and antagonist binding to the histamine H₄ receptor.
Istyastono EP; de Graaf C; de Esch IJ; Leurs R
Curr Top Med Chem; 2011; 11(6):661-79. PubMed ID: 21261593
[TBL] [Abstract][Full Text] [Related]
18. Synthesis and pharmacological identification of neutral histamine H1-receptor antagonists.
Govoni M; Bakker RA; van de Wetering I; Smit MJ; Menge WM; Timmerman H; Elz S; Schunack W; Leurs R
J Med Chem; 2003 Dec; 46(26):5812-24. PubMed ID: 14667234
[TBL] [Abstract][Full Text] [Related]
19. Delineation of agonist binding to the human histamine H4 receptor using mutational analysis, homology modeling, and ab initio calculations.
Jongejan A; Lim HD; Smits RA; de Esch IJ; Haaksma E; Leurs R
J Chem Inf Model; 2008 Jul; 48(7):1455-63. PubMed ID: 18553960
[TBL] [Abstract][Full Text] [Related]
20. Synthesis and structure-activity relationships of cyanoguanidine-type and structurally related histamine H4 receptor agonists.
Igel P; Geyer R; Strasser A; Dove S; Seifert R; Buschauer A
J Med Chem; 2009 Oct; 52(20):6297-313. PubMed ID: 19791743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
